p21(WAF1/Cip1) is associated with cyclin D1(CCND1) expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma

Journal of Pathology

Volumn 184, Issue 3, 1998, Pages 265-271

  Rey, Maria J ^a   Fernández, Pedro L ^a   Jares, Pedro ^a   Muñoz, Montserrat ^a   Nadal, Alfons ^a   Peiró, Nerea ^a   Nayach, Irazema ^a   Mallofré, Carmen ^a   Muntané, Jaume ^a   Campo, Elåffias ^a   Estapé, Jordi ^a   Cardesa, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast; CCND1; Cyclin D1; p21; p53; WAF1

Indexed keywords

CYCLIN D1; CYTOKERATIN 19; ESTROGEN RECEPTOR; PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; TUMOR PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CELL DIVISION; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; LUNG CARCINOMA; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2642641300     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8     Document Type: Article

References (44)

1. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992; 71: 505-514.
2. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
3. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371: 534-537.
4. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
5. el-Deiry WS, Tokino T, Velculescu VE, et al. Wafl, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
6. Spitkovsky D, Steiner P, Gopalkrishnan RV, Eilers M, Jansen-Durr P. The role of p53 in coordinated regulation of cyclin D1 and p21 gene expression by the adenovirus E1A and E1B oncogene. Oncogene 1995; 10: 2421-2425.
7. Chen X, Bargonetti J, Prives C. p53, through p21 (waf/cip1), induces cyclin d1 synthesis . Cancer Res 1995; 55: 4257-4263.
8. Missero C, Calautti E, Eckner R, et al. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 1995; 92: 5451-5455.
9. Parker SB, Eichele G, Zhang P, et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-1027.
10. El-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-2919.
11. Doglioni C, Pelosio P, Laurino L, et al. p21/WAF/CIP1 expression in normal mucosa and in adenocarcinomas of the colon: its relationship with differentiation. J Pathol 1996; 179: 248-253.
12. Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996; 12: 1319-1324.
13. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-854.
14. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
15. Elbendary A, Berchuck A, Davis P, et al. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 1994; 5: 1301-1307.
16. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
17. Barboule N, Mazars P, Baldin V, et al. Expression of p21waf1/cip1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995; 63: 611-615.
18. Schwaller J, Koeffler HP, Loetscher P, Nagel S, Fey MF, Tobler A. Posttranscriptional stabilization underlies p53-independent induction of p21/WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest 1995; 95: 973-979.
19. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by p21WAF1. Cancer Res 1995; 55: 4536-4539.
20. Bae I, Fan S, Bhatia K, Kohn KW, Fornace AJ Jr, O'Connor PM. Relationships between g1 arrest and stability of the p53 and p21cip1/waf1 proteins following gamma-irradiation of human lymphoma cells. Cancer Res 1995; 55: 2387-2393.
21. Balbin M, Hannon GJ, Pendás AM, et al. Functional analysis of a p21WAF1/Cip1/SDI1 mutant (Arg94Trp) identified in a human breast carcinoma. J Biol Chem 1996; 271: 15782-15786.
22. Musgrove EA, Lilischkis R, Cornish AL, et al. Expression of the cyclin-dependent kinase inhibitors p16ink4, p15ink4b and p21waf1/cip1 in human breast cancer. Int J Cancer 1995; 63: 584-591.
23. Li YJ, Laurent-Puig P, Salmon RJ, Thomas G, Hamelin R. Polymorphisms and probable lack of mutation in the waf1-cip1 gene in colorectal cancer. Oncogene 1995; 10: 599-601.
24. Shiohara M, el-Deiry WS, Wada M, et al. Absence of waf1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-3784.
25. Sun Y, Hildesheim A, Li H, et al. No point mutation but a codon 31set-arg polymorphism of the waf-1/cip-1/p21 tumor suppressor gene in naso-pharyngeal carcinoma (npc): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev 1995; 4: 261-267.
26. Tenan M, Carrara F, DiDonato S, Finocchiaro G. Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CKI gene in malignant gliomas. Int J Cancer 1995; 62: 115-117.
27. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin-dependent kinase inhibitor p21/WAF1/CIP1, in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996; 180: 122-128.
28. Elbendary AA, Cirisano FD, Evans AC Jr, et al. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 1996; 2: 1571-1575.
29. Gudas J, Nguyen H, Li T, Hill D, Cowan KH. Effects of cell cycle, wild-type p53 and DNA damage on p21/CIP1/Waf1 expression in human breast epithelial cells. Oncogene 1995; 11: 253-261.
30. Sheikh MS, Li X, Chen J, Shao Z, Ordonez JV,Fontana JA. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 1994; 9: 3407-3415.
31. Upadhyay S, Li G, Liu H, Chen YQ, Sarkar FH, Kim HC. bcl-2 suppresses expression of p21 WAF1CIP1 in breast epithelial cells. Cancer Res 1995; 55: 4520-4524.
32. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21WAF1 and p53 expression in breast carcinoma: an immunohistochemical study of 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591-1599.
33. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996; 93: 1093-1096.
34. Hurlimann J, Chaubert P, Benhattar J. p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994; 7: 423-428.
35. Gillet C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817.
36. Jares P, Rey MJ, Fernández PL, et al. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with proliferation and oestrogen receptor status. J Pathol 1997; 182: 160-166.
37. Elston CW, Ellis OI. Pathology and breast screening. Histopathology 1990; 16: 109-118.
38. WAF1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997; 89: 272-280.
39. Lukas J, Groshen S, Saffari B, et al. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 1997; 150: 167-175.
40. Bhargava V, Thor A, Deng G, et al. The association of p53 immuno-positivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 1994; 7: 361-368.
41. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 1995; 11: 1899-1905.
42. Akashi M, Hachiya M, Osawa Y, Spirin K, Suzuki G, Koeffler HP. Irradiation induces waf1 expression through a p53-independent pathway in kg-1 cells. J Biol Chem 1995; 270: 19181-19187.
43. Lui Y, Martindale JL, Gorospe M, Holbrook NJ. Regulation of p21WAF1/ CIP1 expression through mitogen-activated protein kinase signalling pathway. Cancer Res 1996; 56: 31-35.
44. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanisms of regulation of waf1/cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 1994; 9: 3407-3415.